🇺🇸 Intravenous Dexamethasone in United States

7 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 7

Most-reported reactions

1. Acute Respiratory Distress Syndrome — 1 report (14.29%)
2. Central Nervous System Vasculitis — 1 report (14.29%)
3. Cerebrovascular Accident — 1 report (14.29%)
4. Klebsiella Bacteraemia — 1 report (14.29%)
5. Meningitis — 1 report (14.29%)
6. Pancytopenia — 1 report (14.29%)
7. Septic Shock — 1 report (14.29%)

Source database →

Frequently asked questions

Is Intravenous Dexamethasone approved in United States?

Intravenous Dexamethasone does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Intravenous Dexamethasone in United States?

University of British Columbia is the originator. The local marketing authorisation holder may differ — check the official source linked above.